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POLYPEPTIDES, NUCLEIC ACID 
MOLECULES, AND METHODS FOR 
SYNTHESIS OF TRITERPENES 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Application Ser. No. 61/517,876 ?led Apr. 27, 2011, the 
entire disclosure of which is incorporated herein by this ref 
erence. 
GOVERNMENT INTEREST 
This invention was made with government support under 
Grant No. CBET-0828817 awarded by the National Science 
Foundation and under grant number 2P20 RR020171 from 
the National Center for Research Resources of the National 
Institutes of Health. The government has certain rights in the 
invention. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to composi 
tions and methods for triterpene synthesis, in particular bot 
ryococcene synthesis. 
INTRODUCTION 
Botryococcus braunii is a colony-forming, freshwater 
green algae reported to accumulate 30 to 86% of its dry 
weight as hydrocarbon oils (1). Three distinct races of B. 
braunii have been described based on the types of hydrocar 
bons that each accumulates (2). Race A accumulates fatty 
acid-derived alkadienes and alkatrienes (3), race L accumu 
lates the tetraterpene lycopadiene (4), and race B accumulates 
triterpenes, predominately botryococcene, squalene and their 
methylated derivatives (5). The oils accumulate both in intra 
cellular oil bodies and in association with an extracellular 
matrix (6), which in race B consists largely of long-chain, 
cross-linked biopolymers formed in part from acetalization of 
polymethylsqualene diols (7). Di- and tetra-methylated bot 
ryococcenes are generally the most abundant triterpenes 
accumulating in race B with smaller amounts of tetramethy 
lated-squalene (8) and other structural derivatives of squalene 
and botryococcene that range from C31 to C37 accumulating 
to various levels in different strains and in response to variable 
culture conditions (9). Other polymethylated derivatives such 
as diepoxy-tetramethylsqualene (10), botryolins (11), and 
brauixanthins (12) have also been reported. 
B. braunii race B has received signi?cant attention because 
it is considered an ancient algal species dating back at least 
500 MYA and is one of the few organisms known to have 
directly contributed to the existing oil and coal shale deposits 
found on Earth (13-15), accounting for up to 1.4% of the total 
hydrocarbon content in oil shales (16). Secondly, because the 
hydrocarbon oils of B. braunii race B are readily converted to 
starting materials for industrial chemical manufacturing and 
high quality fuels under standard hydrocracking/distillation 
conditions in yields approaching 97% (FIG. 1A) (17), race B 
has been considered a potential production host for renewable 
petrochemicals and biofuels. However, the slow growth habit 
of B. braunii poses serious limitations to its suitability as a 
robust biofuel production system. 
There remains a need in the art to harness this unique oil 
biosynthetic capacity for use in a system that allows for more 
rapid and higher yield production. 
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SUMMARY 
The presently-disclosed subject matter meets some or all of 
the above-identi?ed needs, as will become evident to those of 
ordinary skill in the art after a study of information provided 
in this document. 
This Summary describes several embodiments of the pres 
ently-disclosed subject matter, and in many cases lists varia 
tions and permutations of these embodiments. This Summary 
is merely exemplary of the numerous and varied embodi 
ments. Mention of one or more representative features of a 
given embodiment is likewise exemplary. Such an embodi 
ment can typically exist with or without the feature(s) men 
tioned; likewise, those features can be applied to other 
embodiments of the presently-disclosed subject matter, 
whether listed in this Summary or not. To avoid excessive 
repetition, this Summary does not list or suggest all possible 
combinations of such features. 
Botryococcene biosynthesis is thought to resemble that of 
squalene, a metabolite essential for sterol metabolism in all 
eukaryotes. Squalene arises from an initial condensation of 
two molecules of farnesyl diphosphate (FPP) to form pre 
squalene diphosphate (PSPP), which then undergoes a reduc 
tive rearrangement to form squalene. In principle, botryococ 
cene could arise from an alternative rearrangement of the 
pre-squalene intermediate. Because of these proposed simi 
larities, the present inventors predicted that a botryococcene 
synthase would resemble squalene synthase and hence iso 
lated squalene synthase-like genes from B. braunii race B. 
While B. braunii does harbor at least one typical squalene 
synthase, none of the other three squalene synthase-like 
(SSL) genes encode for botryococcene biosynthesis directly. 
SSL-l catalyzes the biosynthesis of PSPP and SSL-2 the 
biosynthesis of bisfamesyl ether, while SSL-3 does not 
appear able to directly utilize FPP as a substrate. However, 
when combinations of the synthase-like enzymes were mixed 
together, in vivo and in vitro, robust botryococcene (SSL-1+ 
SSL-3) or squalene biosynthesis (SSL1+SSL-2) was 
observed. These ?ndings were unexpected because squalene 
synthase, an ancient and likely progenitor to the other B02 
ryococcus triterpene synthases, catalyzes a two-step reaction 
within a single enzyme unit without intermediate release, yet 
in B. braunii, these activities appear to have separated and 
evolved inter-dependently for specialized triterpene oil pro 
duction greater than 500 MYA. Co-expression of the SSL-l 
and SSL-3 genes in different con?gurations, as independent 
genes, as gene fusions, or targeted to intracellular mem 
branes, also demonstrate the potential for engineering even 
greater ef?ciencies of botryococcene biosynthesis. 
The presently-disclosed subject matter includes an isolated 
polypeptide having triterpene synthase activity wherein the 
polypeptide includes a peptide domain selected from 
domains I, II, III, IV, and V, wherein domain I comprises an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 17, domain II comprises an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 18, domain III comprises an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 19, domain IV comprises an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 20, and domainV comprises an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 21. In some embodiments of 
the isolated polypeptide, domain I comprises the amino acid 
sequence of SEQ ID NO: 17, domain II comprises the amino 
acid sequence of SEQ ID NO: 18, domain III comprises the 
amino acid sequence of SEQ ID NO: 19, domain IV com 
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prises the amino acid sequence of SEQ ID NO: 20, and 
domainV comprises the amino acid sequence of SEQ ID NO: 
21. In some embodiments of the isolated polypeptide, the 
polypeptide comprises peptide domains I, II, III, IV, andV. In 
some embodiments, the isolated polypeptide includes the 
amino acid sequence of SEQ ID NO: 16. In some embodi 
ments, the polypeptide has triterpene synthase activity. In 
some embodiments, the isolated polypeptide includes an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 16. 
The presently-disclosed subject matter furthering includes 
an isolated nucleic acid, encoding the polypeptide including a 
peptide domain selected from domains I, II, III, IV, and V, 
Wherein domainI comprises an amino acid sequence that is at 
least 60% identical to the amino acid sequence of SEQ ID 
NO: 17, domain II comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 18, domain III comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 19, domain IV comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 20, and domainV comprises an amino acid sequence that 
is at least 60% identical to the amino acid sequence of SEQ ID 
NO: 21. In some embodiments the isolated nucleic acid fur 
ther encodes a second polypeptide having triterpene synthase 
activity Wherein the second polypeptide comprises a peptide 
domain selected from domains I, II, III, IV, and V, Wherein 
domain I comprises an amino acid sequence that is at least 
65% identical to the amino acid sequence of SEQ ID NO: 3, 
domain II comprises an amino acid sequence that is at least 
65% identical to the amino acid sequence of SEQ ID NO: 4, 
domain III comprises an amino acid sequence that is at least 
60% identical to the amino acid sequence of SEQ ID NO: 5, 
domain IV comprises an amino acid sequence that is at least 
80% identical to the amino acid sequence of SEQ ID NO: 6, 
and domain V comprises an amino acid sequence that is at 
least 60% identical to the amino acid sequence of SEQ ID 
NO: 7. In some embodiments of the presently-disclosed sub 
ject matter a vector comprising the nucleic acid(s) is pro 
vided. 
In some embodiments of the presently-disclosed subject 
matter a host cell transfected With the nucleic acid(s) is pro 
vided. In some embodiments, the host cell is further trans 
fected With a nucleic acid molecule encoding a famesyl 
diphosphate synthase, a triterpene methyltransferase, a 
squalene methyltransferase, or a botryococcene methyltrans 
ferase. 
In some embodiments of the presently-disclosed subject 
matter an isolated polypeptide having triterpene synthase 
activity Wherein the polypeptide comprises a peptide domain 
selected from domains I, II, III, IV, andV, Wherein: domainI 
comprises an amino acid sequence that is at least 60% iden 
tical to the amino acid sequence of SEQ ID NO: 10, domain 
II comprises an amino acid sequence that is at least 60% 
identical to the amino acid sequence of SEQ ID NO: 11, 
domain III comprises an amino acid sequence that is at least 
60% identical to the amino acid sequence of SEQ ID NO: 12, 
domain IV comprises an amino acid sequence that is at least 
60% identical to the amino acid sequence of SEQ ID NO: 13, 
and domain V comprises an amino acid sequence that is at 
least 60% identical to the amino acid sequence of SEQ ID 
NO: 14. In some embodiments of the isolated polypeptide 
domainI comprises the amino acid sequence of SEQ ID NO: 
10, domain II comprises the amino acid sequence of SEQ ID 
NO: 11, domain III comprises the amino acid sequence of 
SEQ ID NO: 12, domain IV comprises the amino acid 
sequence of SEQ ID NO: 13, and domain V comprises the 
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amino acid sequence of SEQ ID NO: 14. In some embodi 
ments the polypeptide comprises peptide domains I, II, III, IV, 
and V. In some embodiments the polypeptide has the amino 
acid sequence of SEQ ID NO: 9. In some embodiments, the 
polypeptide has triterpene synthase activity. In some embodi 
ments, the polypeptide comprises an amino acid sequence 
that is at least 60% identical to the amino acid sequence of 
SEQ ID NO: 9. 
The presently-disclosed subject matter further includes an 
isolated nucleic acid, encoding the polypeptide comprising a 
peptide domain selected from domains I, II, III, IV, and V, 
Wherein: domain I comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 10, domain II comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 11, domain III comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 12, domain IV comprises an amino acid sequence that is 
at least 60% identical to the amino acid sequence of SEQ ID 
NO: 13, and domainV comprises an amino acid sequence that 
is at least 60% identical to the amino acid sequence of SEQ ID 
NO: 14. In some embodiments, the nucleic acid further 
encodes a second polypeptide having triterpene synthase 
activity Wherein the second polypeptide comprises a peptide 
domain selected from domains I, II, III, IV, andV, Wherein: 
domain I comprises an amino acid sequence that is at least 
65% identical to the amino acid sequence of SEQ ID NO: 3, 
domain II comprises an amino acid sequence that is at least 
65% identical to the amino acid sequence of SEQ ID NO: 4, 
domain III comprises an amino acid sequence that is at least 
60% identical to the amino acid sequence of SEQ ID NO: 5, 
domain IV comprises an amino acid sequence that is at least 
80% identical to the amino acid sequence of SEQ ID NO: 6, 
and domain V comprises an amino acid sequence that is at 
least 60% identical to the amino acid sequence of SEQ ID 
NO: 7. In some embodiments of the presently-disclosed sub 
ject matter a vector comprising the nucleic acid(s) is pro 
vided. 
In some embodiments of the presently-disclosed subject 
matter a host cell transfected With the nucleic acid(s) is pro 
vided. In some embodiments, the host cell is further trans 
fected With a nucleic acid molecule encoding a famesyl 
diphosphate synthase, a triterpene methyltransferase, a 
squalene methyltransferase, or a botryococcene methyltrans 
ferase. 
The presently-disclosed subject matter further includes a 
method for producing triterpenes including: (a) providing a 
cell transfected With (i) a nucleic acid encoding a polypeptide 
having triterpene synthase activity Wherein the polypeptide 
comprises a peptide domain selected from domains I, II, III, 
IV, and V, Wherein: domain I comprises an amino acid 
sequence that is at least 60% identical to the amino acid 
sequence of SEQ ID NO: 17, domain II comprises an amino 
acid sequence that is at least 60% identical to the amino acid 
sequence of SEQ ID NO: 18, domain III comprises an amino 
acid sequence that is at least 60% identical to the amino acid 
sequence of SEQ ID NO: 19, domain IV comprises an amino 
acid sequence that is at least 60% identical to the amino acid 
sequence of SEQ ID NO: 20, and domain V comprises an 
amino acid sequence that is at least 60% identical to the amino 
acid sequence of SEQ ID NO: 21; or (ii) a nucleic acid 
encoding a polypeptide having triterpene synthase activity 
Wherein the polypeptide comprises a peptide domain selected 
from domains I, II, III, IV, and V, Wherein: domain I com 
prises an amino acid sequence that is at least 60% identical to 
the amino acid sequence of SEQ ID NO: 10, domain II com 
prises an amino acid sequence that is at least 60% identical to 
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the amino acid sequence of SEQ ID NO: 11, domain III 
comprises an amino acid sequence that is at least 60% iden 
tical to the amino acid sequence of SEQ ID NO: 12, domain 
IV comprises an amino acid sequence that is at least 60% 
identical to the amino acid sequence of SEQ ID NO: 13, and 
domain V comprises an amino acid sequence that is at least 
60% identical to the amino acid sequence of SEQ ID NO: 14; 
and (b) culturing the transfected cell under conditions suit 
able for production of triterpenes. 
In some embodiments of the method the cell is further 
transfected with a second nucleic acid encoding a second 
polypeptide having triterpene synthase activity wherein the 
second polypeptide comprises a peptide domain selected 
from domains I, II, III, IV, and V, wherein: domain I com 
prises an amino acid sequence that is at least 65% identical to 
the amino acid sequence of SEQ ID NO: 3, domain II com 
prises an amino acid sequence that is at least 65% identical to 
the amino acid sequence of SEQ ID NO: 4, domain III com 
prises an amino acid sequence that is at least 50% identical to 
the amino acid sequence of SEQ ID NO: 5, domain IV com 
prises an amino acid sequence that is at least 80% identical to 
the amino acid sequence of SEQ ID NO: 6, and domain V 
comprises an amino acid sequence that is at least 40% iden 
tical to the amino acid sequence of SEQ ID NO: 7. In some 
embodiments, the method further includes isolating triter 
pene from the cultured cells. 
The presently-disclosed subject matter further includes a 
kit for producing triterpenes, including (a) a ?rst polypeptide 
having triterpene synthase activity wherein the polypeptide 
comprises a peptide domain selected from domains I, II, III, 
IV, and V, wherein: domain I comprises an amino acid 
sequence that is at least 60% identical to the amino acid 
sequence of SEQ ID NO: 17 or at least 60% identical to the 
amino acid sequence of SEQ ID NO: 10, domain II comprises 
an amino acid sequence that is at least 60% identical to the 
amino acid sequence of SEQ ID NO: 18 or at least 60% 
identical to the amino acid sequence of SEQ ID NO: 11, 
domain III comprises an amino acid sequence that is at least 
60% identical to the amino acid sequence of SEQ ID NO: 19 
or at least 60% identical to the amino acid sequence of SEQ 
ID NO: 12, domain IV comprises an amino acid sequence that 
is at least 60% identical to the amino acid sequence of SEQ ID 
NO: 20 or at least 60% identical to the amino acid sequence of 
SEQ ID NO: 13, and domain V comprises an amino acid 
sequence that is at least 60% identical to the amino acid 
sequence of SEQ ID NO: 21 or at least 60% identical to the 
amino acid sequence of SEQ ID NO: 14; and (b) a second 
polypeptide having triterpene synthase activity wherein the 
second polypeptide comprises a peptide domain selected 
from domains I, II, III, IV, and V, wherein: domain I com 
prises an amino acid sequence that is at least 65% identical to 
the amino acid sequence of SEQ ID NO: 3, domain II com 
prises an amino acid sequence that is at least 65% identical to 
the amino acid sequence of SEQ ID NO: 4, domain III com 
prises an amino acid sequence that is at least 50% identical to 
the amino acid sequence of SEQ ID NO: 5, domain IV com 
prises an amino acid sequence that is at least 80% identical to 
the amino acid sequence of SEQ ID NO: 6, and domain V 
comprises an amino acid sequence that is at least 40% iden 
tical to the amino acid sequence of SEQ ID NO: 7. In some 
embodiments of the kit, the ?rst polypeptide is provided in a 
?rst container, and the second polypeptide is provided in a 
second container. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1A includes an overview of the hydrocracking pro 
cess of a typical C34 botryococcene to yield fuel suitable for 
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combustion engines; brie?y, botryococcenes are treated with 
high pressure H2 at high temperatures with a Pd catalyst to 
give a variety of organic molecules, which can be further 
distilled into various classes of fuel. 
FIG. 1B includes biosynthetic pathways for botryococcene 
and squalene; both triterpenes are derived from an initial 
condensation of two FPP molecules to form presqualene 
diphosphate (PSPP), which is subsequently cleaved and 
reduced to form either botryococcene or squalene. 
FIG. 2 includes an amino acid alignment of BSS (SEQ ID 
NO: 22), SSL-1 (SEQ ID NO: 2), SSL-2 (SEQ ID NO: 9), and 
SSL-3 (SEQ ID NO: 16 from B. braunii race B. Five highly 
conserved domains amongst squalene synthase’s identi?ed 
by Robinson et al. (Mol Cell Biol 13:2706-2717) and the 
“FLAP” and putative NADPH binding site identi?ed by Gu et 
al. (JBiol Chem 273:12515-12525) are boxed. Amino acids 
completely conserved in the squalene synthase of B. braunii 
(AF205791), C. reinhardlii (XM001703395), A. Zhaliana 
(NM119630), N. Zabacum (U60057), H. sapiens 
(NM004462), R. norvegicus (NM019238), S. cereviseae 
0(59959), S. pombe (NM001021271), and Y. lipolylica 
(AF092497), plus those residues also conserved with these 
squalene synthases and dehydrosqualene synthase (CrtM) 
from S. aureus (AM920687), are labeled above the align 
ment. Residues of CrtM identi?ed by Lin et al. (Proc Natl 
Acad Sci USA 107:21337-21342) as important for the ?rst 
and second half reactions are labeled with a star. Possible 
membrane spanning regions of BSS and SSL2 as predicted by 
TMpred are underlined. In the subsequent studies, a 3' trun 
cated form of SSL2 (tr2) missing the putative membrane 
spanning domain after D392 (indicated by arrow) was heter 
ologously expressed in bacteria. 
FIG. 3 includes an alignment comparison of selection 
regions/domains of sequence for Bolryococcus braunii race 
B squalene synthase-like 1, 2, and 3, (SSL-1, SSL-2, and 
SSL-3), and Bolryococcus squalene synthase (BSS). 
Sequences displayed across the ?ve domains are: SSL1, SEQ 
ID NO: 3, 4, 5, 6, and 7; SSL-2, SEQ ID NO: 10,11,12,13, 
and 14; SSL-3, SEQ ID NO: 17, 18, 19, 20, and 21; and BSS, 
SEQ ID NO: 23, 24, 25, 26, and 27. 
FIG. 4 depicts the dependence of the squalene synthase 
like-1 enzyme on algal lysate for botryococcene biosynthesis. 
Puri?ed SSL-1 enzyme (1 pg) (SSL-1), B. braunii 2000 g 
whole-cell lysate (10 pg protein) (Lys), and equal aliquots of 
both SSL-1 and lysate were incubated with radiolabeled FPP, 
with (+) or without (—) 2 mM NADPH and the incorporation 
into squalene and botryococcene determined by TLC separa 
tion of the reaction products followed by scintillation count 
ing of the corresponding zones (panel A). Increasing amounts 
of puri?ed SSL-1 were incubated with 10 pg of B. braunii 
2000 g whole-cell lysate and the incorporation of radiola 
beled FPP into squalene and botryococcene determined by 
TLC separation/scintillation counting (panel B). B. braunii 
2000 g whole-cell lysates were prepared from cells collected 
at the indicated times (weeks) after subculturing, and aliquots 
containing 10 pg of protein were incubated without (—) or 
with (+) 1 pg of puri?ed SSL-1 protein, and incorporation of 
radiolabeled FPP into squalene and botryococcene deter 
mined (panel C). The SSL-1 gene containing a 5' terminal 
sequence coding for a hexa-histidine tag was over-expressed 
in E. coli and the corresponding enzyme puri?ed by cobalt 
a?inity chromatography according to the manufacturer 
(Sigma). B. braunii lysate was prepared from cells collected 
at the indicated stages of culture development according to 
the procedure described by Okada, S. et al. (Arch Biochem 
Biophys 422: 110-118) and 10 pg of lysate protein was used 
per assay. Assays were incubated at 37° C. for 1 h, then the 
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reaction products extracted with hexane. Aliquots of the hex 
ane extracts was separated by silica TLC and the radioactivity 
migrating to zones corresponding to authentic standards of 
botryococcene and squalene determined by scintillation 
counting. Data represents mean:s.e.m. 
FIG. 5 depicts Michaelis-Menten enzyme kinetics of the 
SSL-1 reaction. Enzyme assays (50 pl) were set up as 
described in the methods section with puri?ed SSL-1 (0.2-1.0 
pg), 0.1% triton X-100, 12 mM NADPH, and the indicated 
concentration of 3 H-FPP. Assays were incubated for 15 min at 
370 C. and stopped by addition of 50 pl 0.5 M EDTA. The 
reactions were then extracted 3>< with 200 pl water saturated 
1-butanol and pooled in a 4 ml glass screw cap vial. The 
butanol was evaporated with a stream of nitrogen gas and the 
white residue was resuspended in 2 ml of acid phosphatase 
solution (20% 1-propanol (v/v), 100 mM sodium acetate pH 
4.7, 0.1% Triton X-100, 10 units sweet potato acid phos 
phatase) and incubated overnight (12-16 h) in a 28° C. shaker. 
Dephosphorylated products were extracted 3>< with 1 ml 
n-hexane, pooled, dried with a stream of nitrogen gas, and 
resuspended in 200 pl of n-hexane. Aliquots of the hexane 
extract were spotted onto reverse-phase TLC plates along 
with standards of FOH and PSOH and developed with metha 
nol:acetone (8:2). The standards were visualized with iodine 
vapors and the zones corresponding to FOH (rf:0.65) and 
PSOH (rf:0.45) were scraped and analyzed by scintillation 
spectroscopy. Addition of NADPH had no signi?cant effect 
on enzyme activity (less than 4% difference) and greater than 
95% of the input radioactivity was recovered as FOH and 
PSOH, indicating that PSPP is the only dominant reaction 
product formed from FPP by the SSL-1 enzyme. The data was 
analyzed using the SigmaPlot Enzyme Kinetics 1.3 software. 
Data represents mean:S.E.M of duplicate assays with and 
triplicate assays without NADPH. 
FIG. 6 depicts the functional characterization of the 
squalene synthase-like genes of Bolryococcus braunii race B. 
The squalene synthase-like genes, SSL-1, SSL-2 and SSL-3, 
were expressed in yeast separately (SSL-1 (B), SSL-2(C) or 
SSL-3(D)) or in combinations (SSL-1+SSL-2(E), SSL-1+ 
SSL-3 (F)) and the hexane extractable metabolites pro?led by 
GC-MS. The chemical pro?le of yeast not engineered with 
any gene constructs serves as the background control (A). The 
SSL genes were also expressed in bacteria, the af?nity-tagged 
proteins puri?ed and assayed separately (SSL-2 (G)) or in 
combinations (SSL-1+SSL-2 (H); SSL-1+SSL-3 (1)) for the 
reaction products generated upon incubation with FPP and 
pro?led by GC-MS (G-l), or for quantitative determination of 
radio labeled FPP incorporated into speci?c reaction products 
separated by TLC (J). Data (J) represents mean:S.E.M. 
obtained from three independent experiments (n:3). The 
chromatograms (A-l) are also annotated for the elution 
behavior of botryococcene (1), squalene (2), presqualene 
alcohol (3) and bisfarnesyl ether (4). 
FIG. 7 includes GC chromatographs of unknown terpene 
puri?ed from yeast overexpressing the SSL-2 gene (A) in 
comparison to chemically synthesized bisfarnesyl ether (B). 
The MS for the dominant peak compounds with retention 
time of 8.38 min in panels A and B are shown in panels C and 
D, respectively. Chemically synthesized bisfarnesyl ether 
produced identical NMR spectrums to the unknown terpene 
puri?ed from yeast over-expressing the SSL-2 gene: 
1H NMR (400 MHz, CDC13) 61.58 (br s, 6), 1.64-1.66 (m, 
18), 1.92-2.14 (m, 16), 3.96 (d, 1:6.8 Hz, 4), 5.04-5.12 (m, 4), 
5.32-5.38 (m, 2); 
13C NMR (100 MHz, CDC13) 6 16.2 (CH2C(CH3): 
CHCH2), 16.7 (CH2C(CH3):CHCH2O), 17.9 (Z4CH3 of 
(CH3)2C:CHCH2), 25.9 (E-CH3 of (CH3)2C:CHCH2), 
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26.5 ((CH3)2C:CHCH2), 26.9 (CH2C(CH3):CHCH2), 
39.8 (CH2C(CH3):CHCH2), 39.9 (CH2C(CH3): 
CHCH2O), 66.6 (CH2C(CH3):CHCHZO), 121.3 (CH2C 
(CH3):CHCH2O), 124.1 ((CH3)2C:CHCH2), 124.5 
(CH2C(CH3):CHCH2), 131.5 ((CH3)2C:CHCH2), 135.4 
(CH2C(CH3):CHCH2), and 140.2 (CH2C(CH3): 
CHCH2O). 
FIG. 8 shows that SSL-3 and SSL-2 utilize PSPP, but not 
FPP, for ef?cient biosynthesis of botryococcene or squalene, 
respectively. Two primary enzyme assays (500 pl) were set up 
with 20 pg of puri?ed SSL-1 or Nicoliana benlhamiana 
squalene synthase (TSS) plus 40 pM 3H-FPP. The assays 
were incubated at 37° C. for 1 h, then extracted 3>< with 500 pl 
water saturated 1-butanol, pooled, and evaporated under a 
stream of nitrogen gas. The white residue was resuspended in 
50 pl of 25 mM NH4HCO3 in 70% ethanol (v/v). An aliquot of 
the resuspension was analyzed by the acid phosphatase assay 
(described in supplemental FIG. 4) and shown to consist of 
45% and 40% PSPP for the SSL-1 and TSS primary incuba 
tions, respectively. The remaining reaction product (55% and 
60%, respectively) in both assays was FPP. It was calculated 
that 1 pl of each resuspension contained ~150 pmoles of 
3H-PSPP. Secondary enzyme assays (50 pl) were set up with 
1 pl of the reaction products isolated from the primary incu 
bations (~3 pM PSPP and ~4 pM FPP), 2 mM NADPH, and 
either 1 pg of SSL-3 or SSL-2 enzyme. For comparison, 
enzyme assays were also set up containing 3 pM 3H-FPP, 2 
mM NADPH and either 1 pg each of SSL-1 plus SSL-3, or 
SSL-1 plus SSL-2. Additional control assays contained 5 pM 
3H-FPP, 2 mM NADPH, and either 1 pg of SSL-3 or SSL-2. 
The reactions were incubated at 370 C. for 15 min, stopped by 
addition of 50 pl 0.5 M EDTA, and extracted with 100 pl 
n-hexane. Aliquots of the hexane extracts, along with stan 
dards of squalene and botryococcene, were separated by 
silica TLC using n-hexane as the developing solvent. Stan 
dards were visualized with iodine vapors and the correspond 
ing zones were analyzed by scintillation spectroscopy. Bot 
ryococcene biosynthesis is shown in blue and squalene 
biosynthesis is shown in red. Data represents mean:S.E.M. 
FIG. 9 describes a proposed mechanism for bisfarnesyl 
ether biosynthesis by SSL-2. When 2 molecules of FPP are 
bound by the SSL-2 enzyme, ionization of the diphosphate 
substituent from one creates a carbocation, which can react 
with a water molecule in close proximity to generate farnesol, 
FOH. If the FOH becomes appropriately positioned relative 
to the second FPP molecule, then a Williamson ether synthe 
sis (32) reaction could occur to yield bisfarnesyl ether. 
FIG. 10 includes a comparison of botryococcene produc 
tion in yeast engineered with different con?gurations of 
SSL-1 and SSL-3. Yeast line TN7 was engineered with the 
SSL-1 and SSL-3 genes on separate plasmids (squares), with 
gene fusions (SSL-1 fused to SSL-3 via a triplet repeat of 
GGSG (triangles), or vice versa (diamonds)), or with 63 or 71 
amino acids of the carboxy terminus of the Bolryococcus 
squalene synthase, sequences containing a membrane span 
ning domain, appended to the carboxy termini of the SSL-1 
and SSL-3 enzymes, respectively (circles). The data repre 
sents mean:S.E.M. 
FIG. 11 depicts the catalytic roles of the squalene synthase 
like enzymes in Bolryococcus braunii race B and their puta 
tive contributions to the triterpene constituents that accumu 
late. The previously identi?ed squalene synthase gene (BSS) 
(31) is thought to provide squalene essential for sterol 
metabolism, whereas the squalene synthase-like genes SSL 
1, SSL-2 and SSL-3 provide for the triterpene oils serving 
specialized functions for the algae. In combination with SSL 
1, SSL-2 could provide squalene for extracellular matrix and 
US 8,822,187 B1 
methylated squalene derivatives, while SSL-l plus SSL-3 
generates botryococcene, which along with its methyl deriva 
tives, accounts for the majority of the triterpene oil. 
BRIEF DESCRIPTION OF THE SEQUENCE 
LISTING 
SEQ ID NO: 1 is a nucleic acid sequence for Bolryococcus 
braunii race B squalene synthase-like 1 (SSL-l). 
SEQ ID NO: 2 is an amino acid sequence for SSL-l. 
SEQ ID NO: 3 is an amino acid sequence for Domain I of 
SSL-1. 
SEQ ID NO: 4 is an amino acid sequence for Domain II of 
SSL-1. 
SEQ ID NO: 5 is an amino acid sequence for Domain III of 
SSL-1. 
SEQ ID NO: 6 is an amino acid sequence for Domain IV of 
SSL-1. 
SEQ ID NO: 7 is an amino acid sequence for DomainV of 
SSL-1. 
SEQ ID NO: 8 is a nucleic acid sequence for Bolryococcus 
braunii race B squalene synthase-like 2 (SSL-2). 
SEQ ID NO: 9 is an amino acid sequence for SSL-2. 
SEQ ID NO: 10 is an amino acid sequence for Domain I of 
SSL-2. 
SEQ ID NO: 1 1 is an amino acid sequence for Domain II of 
SSL-2. 
SEQ ID NO: 12 is an amino acid sequence for Domain III 
of SSL-2. 
SEQ ID NO: 13 is an amino acid sequence for Domain IV 
of SSL-2. 
SEQ ID NO: 14 is an amino acid sequence for DomainV of 
SSL-2. 
SEQ ID NO: 15 is a nucleic acid sequence for Bolryococ 
cus braunii race B squalene synthase-like 2 (SSL-3). 
SEQ ID NO: 16 is an amino acid sequence for SSL-3. 
SEQ ID NO: 17 is an amino acid sequence for Domain I of 
SSL-3. 
SEQ ID NO: 18 is an amino acid sequence for Domain II of 
SSL-3. 
SEQ ID NO: 19 is an amino acid sequence for Domain III 
of SSL-3. 
SEQ ID NO: 20 is an amino acid sequence for Domain IV 
of SSL-3. 
SEQ ID NO: 21 is an amino acid sequence for DomainV of 
SSL-3. 
SEQ ID NO: 22 is an amino acid sequence for Bolryococ 
cus squalene synthase (BSS). 
SEQ ID NO: 23 is an amino acid sequence for Domain I of 
BSS. 
SEQ ID NO: 24 is an amino acid sequence for Domain II of 
BSS. 
SEQ ID NO: 25 is an amino acid sequence for Domain III 
of BSS. 
SEQ ID NO: 26 is an amino acid sequence for Domain IV 
of BSS. 
SEQ ID NO: 27 is an amino acid sequence for DomainV of 
BSS. 
SEQ ID NOS: 28-45 are nucleic acid sequences for nucle 
otide primers. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
?cations to embodiments described in this document, and 
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other embodiments, will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the speci?c details of the described exemplary 
embodiments, is provided primarily for cleamess of under 
standing and no unnecessary limitations are to be understood 
therefrom. In case of con?ict, the speci?cation of this docu 
ment, including de?nitions, will control. 
Some of the polynucleotide and polypeptide sequences 
disclosed herein are cross-referenced to GENBANK®/GEN 
PEPT® accession numbers. The sequences cross-referenced 
in the GENBANK®/GENPEPT® database are expressly 
incorporated by reference as are equivalent and related 
sequences present in GENBANK®/GENPEPT® or other 
public databases. Also expressly incorporated herein by ref 
erence are all annotations present in the GENBANK®/GEN 
PEPT® database associated with the sequences disclosed 
herein. Unless otherwise indicated or apparent, the references 
to the GENBANK®/GENPEPT® database are references to 
the most recent version of the database as of the ?ling date of 
this Application. 
The following are relevant GENBANK® accession num 
bers: Bolryococcus braunii race B squalene synthase-like 1 
(SSL-l), -2 (SSL-2), and 3 (SSL-3), respectively, 
iHQ585058; HQ585059, and HQ585060. 
While the terms used herein are believed to be well under 
stood by one of ordinary skill in the art, de?nitions are set 
forth to facilitate explanation of the presently-disclosed sub 
ject matter. 
Unless de?ned otherwise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently 
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are now described. 
Following long-standing patent law convention, the terms 
“a”, “an”, and “the” refer to “one or more” when used in this 
application, including the claims. Thus, for example, refer 
ence to “a cell” includes a plurality of such cells, and so forth. 
Unless otherwise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about”. Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” when referring to a value 
or to an amount of mass, weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments:20%, in some embodiments 110%, in some 
embodiments 15%, in some embodiments 11%, in some 
embodiments 10.5%, and in some embodiments 10.1% from 
the speci?ed amount, as such variations are appropriate to 
perform the disclosed method. By way of providing an 
example, about 60% is inclusive of: 60%:0.1%, which is 
inclusive of 59.9%-60.1%, and so forth. 
As used herein, ranges can be expressed as from “about” 
one particular value, and/or to “about” another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as “about” that particular value in addition to the value itself. 
For example, if the value “10” is disclosed, then “about 10” is 
also disclosed. It is also understood that each unit between 
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two particular units are also disclosed. For example, if 10 and 
15 are disclosed, then 11, 12, 13, and 14 are also disclosed. 
The presently-disclosed subject matter includes polypep 
tides, nucleic acid molecules, vectors, transfected cells, and 
methods for their use. The polypeptides of the presently 
disclosed subject matter include, for example, polypeptides 
comprising the amino acid sequence set forth in SEQ ID NO: 
2, 9, or 16, and fragments thereof. In some embodiments, the 
polypeptide fragments have triterpene synthase activity. 
In some embodiments, the polypeptides comprise one or 
more peptide domains I, II, III, IV, V and IV, wherein domain 
I comprises LPQELQDPICIFYL (SEQ ID NO: 3), LPDEL 
RHPICVFYL (SEQ ID NO: 10), or LPEVLQDPICVNYL 
(SEQ ID NO: 17); domain II comprises LRALDTVED 
DMNLKSETK (SEQ ID NO: 4), LRALDTVEDDMNLP 
NEVK (SEQ ID NO: 11), or LRGLDTLQDDMAIPAEKR 
(SEQ ID NO: 18); domain III comprises YCHYVAGSCGIA 
VTKVIV (SEQ ID NO: 5), YCHYVAGLVGSAVAKIFV 
(SEQ ID NO: 12), or YAFTNNGPVAICLTKLWV (SEQ ID 
NO: 19); domain IV comprises GLLLQKANIITDYNED 
(SEQ ID NO: 6), GQFLQKTNVIRDYLED (SEQ ID NO: 
13), or AMFLGKINVIRDIKED (SEQ ID NO: 20); and 
domainV comprises ALALLLVTAFGHLS (SEQ ID NO: 7), 
SCLIPEVMGLRTLT (SEQ ID NO: 14), or FCAVPELMS 
LATIS (SEQ ID NO: 21). 
The polypeptides of the presently-disclosed subject matter 
can also contain one or more modi?ed amino acids. The 
presence of modi?ed amino acids can be advantageous in, for 
example, increasing triterpene synthase catalytic activity or 
increasing polypeptide stability. Amino acid(s) are modi?ed, 
for example, co-translationally or post-translationally during 
recombinant production (e.g., N-linked glycosylation at 
N-X-S/T motifs during expression in mammalian cells) or 
modi?ed by synthetic means. Accordingly, a “mutant”, “vari 
ant” or “modi?ed” protein, enzyme, polynucleotide, gene, or 
cell, means a protein, enzyme, polynucleotide, gene, or cell, 
that has been altered or derived, or is in some way different or 
changed, from a parent protein, enzyme, polynucleotide, 
gene, or cell. A mutant or modi?ed protein or enzyme is 
usually, although not necessarily, expressed from a mutant 
polynucleotide or gene. 
A “parent” protein, enzyme, polynucleotide, gene, or cell, 
is any protein, enzyme, polynucleotide, gene, or cell, from 
which any other protein, enzyme, polynucleotide, gene, or 
cell, is derived or made, using any methods, tools or tech 
niques, and whether or not the parent is itself native or mutant. 
A parent polynucleotide or gene encodes for a parent protein 
or enzyme. 
A “mutation” means any process or mechanism resulting 
in a mutant protein, enzyme, polynucleotide, gene, or cell. 
This includes any mutation in which a protein, enzyme, poly 
nucleotide, or gene sequence is altered, and any detectable 
change in a cell arising from such a mutation. Typically, a 
mutation occurs in a polynucleotide or gene sequence, by 
point mutations, deletions, or insertions of single or multiple 
nucleotide residues. A mutation includes polynucleotide 
alterations arising within a protein-encoding region of a gene 
as well as alterations in regions outside of a protein-encoding 
sequence, such as, but not limited to, regulatory or promoter 
sequences. A mutation in a gene can be “silent”, i.e., not 
re?ected in an amino acid alteration upon expression, leading 
to a “sequence-conservative” variant of the gene. This gener 
ally arises because of degeneracy of the genetic code wherein 
more than one codon codes for the same amino acid. 
Non-limiting examples of a modi?ed amino acid include a 
glycosylated amino acid, a sulfated amino acid, a prenlyated 
(e. g., farnesylated, geranylgeranylated) amino acid, an acety 
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lated amino acid, an acylated amino acid, a pegylated amino 
acid, a biotinylated amino acid, a carboxylated amino acid, a 
phosphorylated amino acid, and the like. References 
adequate to guide one of skill in the modi?cation of amino 
acids are replete throughout the literature. Example protocols 
are found in Walker (1998) Protein Protocols on CD-ROM 
(Humana Press, Towata, N.J.). 
In some embodiments, the polypeptides of the presently 
disclosed subject matter include up to 35, 25, 10, 5, 4, 3, 2 or 
1 non-conservative amino acid substitutions. 
Recombinant methods for producing and isolating the trit 
erpene synthase polypeptides and modi?ed triterpene syn 
thase polypeptides of the presently-disclosed subject matter 
are described herein. In addition to recombinant production, 
the polypeptides may be produced by direct peptide synthesis 
using solid-phase techniques (e.g., Stewart et al. (1969) 
Solid-Phase Peptide Synthesis (WH Freeman Co, San Fran 
cisco); and Merri?eld (1963) J. Am. Chem. Soc. 85: 2149 
2154; each of which is incorporated by reference). Peptide 
synthesis may be performed using manual techniques or by 
automation. Automated synthesis may be achieved, for 
example, using Applied Biosystems 431A Peptide Synthe 
sizer (Perkin Elmer, Foster City, Calif.) in accordance with 
the instructions provided by the manufacturer. 
A “protein” or “polypeptide”, which terms are used inter 
changeably herein, comprises one or more chains of chemical 
building blocks called amino acids that are linked together by 
chemical bonds called peptide bonds. An “enzyme” means 
any substance, composed wholly or largely of protein, that 
catalyzes or promotes, more or less speci?cally, one or more 
chemical or biochemical reactions. A “native” or “wild-type” 
protein, enzyme, polynucleotide, gene, or cell, means a pro 
tein, enzyme, polynucleotide, gene, or cell that occurs in 
nature (whose form predominates in natural populations). 
Accordingly, in various embodiments, isolated or recom 
binant polypeptides comprising the amino acid sequence set 
forth in SEQ ID NO: 2, SEQ ID NO: 9, and SEQ ID NO: 16 
are provided. The polypeptides include up to 35, 25, 10, 5, 4, 
3, 2 or 1 conservative amino acid substitutions. 
“Conservative amino acid substitutions” or, simply, “con 
servative variations” of a particular sequence refers to the 
replacement of one amino acid, or series of amino acids, with 
essentially identical amino acid or series of amino acids. One 
of skill will recognize that individual substitutions, deletions 
or additions which alter, add or delete a single amino acid or 
a percentage of amino acids in an encoded sequence result in 
“conservative variations” where the alterations result in the 
deletion of an amino acid, addition of an amino acid, or 
substitution of an amino acid with a functionally similar 
amino acid. 
Conservative substitution tables providing functionally 
similar amino acids are well known in the art. For example, 
one conservative substitution group includes Alanine (A), 
Serine (S), and Threonine (T). Another conservative substi 
tution group includes Aspartic acid (D) and Glutamic acid 
(E). Another conservative substitution group includes Aspar 
agine (N) and Glutamine (Q). Yet another conservative sub 
stitution group includesArginine (R) and Lysine (K). Another 
conservative substitution group includes Isoleucine, (I) Leu 
cine (L), Methionine (M), and Valine (V). Another conserva 
tive substitution group includes Phenylalanine (F), Tyrosine 
(Y), and Tryptophan (W). 
Thus, “conservative amino acid substitutions” of a listed 
polypeptide sequence (e.g., SEQ ID N012, SEQ ID NO: 8, or 
SEQ ID NO: 15) include substitutions of a percentage, typi 
cally less than 10%, of the amino acids of the polypeptide 
sequence, with an amino acid of the same conservative sub 
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stitution group. Accordingly, a conservatively substituted 
variation of a polypeptide of the presently-disclosed subject 
matter can contain, for example, substitutions of 35, 25, 10, 5, 
4, 3, 2 or 1 amino acid with an amino acid of the same 
conservative substitution group. 
It is understood that the addition of sequences that do not 
alter the encoded activity of a nucleic acid molecule, such as 
the addition of a non-functional or non-coding sequence, is a 
conservative variation of the basic nucleic acid molecule. The 
“activity” of an enzyme is a measure of its ability to catalyze 
a reaction, i.e., to “function”, and may be expressed as the rate 
at which the product of the reaction is produced. For example, 
enzyme activity can be represented as the amount of product 
produced per unit of time or per unit of enzyme (e.g., con 
centration or weight), or in terms of af?nity or dissociation 
constants. As used interchangeably herein a “triterpene syn 
thase activity”, “biological activity of triterpene synthase” or 
“functional activity of triterpene synthase”, refers to an activ 
ity exerted by a triterpene synthase protein, polypeptide or 
nucleic acid molecule on a triterpene synthase polypeptide 
substrate, as determined in vivo, or in vitro, according to 
standard techniques. 
One of skill in the art will appreciate that many conserva 
tive substitutions of the nucleic acid constructs which are 
disclosed herein yield a functionally identical construct. For 
example, owing to the degeneracy of the genetic code, “silent 
substitutions” (i.e., substitutions in a nucleic acid sequence 
which do not result in an alteration in an encoded polypep 
tide) are an implied feature of every nucleic acid sequence 
which encodes an amino acid. 
Similarly, “conservative amino acid substitutions,” in 
which one or a few amino acids in an amino acid sequence are 
substituted with different amino acids with highly similar 
properties, are also readily identi?ed as being highly similar 
to a disclosed construct. Families of amino acid residues 
having similar side chains have been de?ned in the art. These 
families include amino acids with basic side chains (e.g., 
lysine, arginine, histidine), acidic side chains (e.g., aspartic 
acid, glutamic acid), uncharged polar side chains (e.g., gly 
cine, asparagine, glutamine, serine, threonine, tyrosine, cys 
teine), nonpolar side chains (e.g., alanine, valine, leucine, 
isoleucine, proline, phenylalanine, methionine, tryptophan), 
beta-branched side chains (e.g., threonine, valine, isoleucine) 
and aromatic side chains (e. g., tyrosine, phenylalanine, tryp 
tophan, histidine). Such conservative variations of each dis 
closed sequence are a feature of the polypeptides provided 
herein. 
It will be appreciated by those skilled in the art that due to 
the degeneracy of the genetic code, a multitude of nucleotide 
sequences encoding modi?ed triterpene synthase polypep 
tides of the presently-disclosed subject matter may be pro 
duced, some of which bear substantial identity to the nucleic 
acid sequences explicitly disclosed herein. For instance, 
codons AGA, AGG, CGA, CGC, CGG, and CGU all encode 
the amino acid arginine. Thus, at every position in the nucleic 
acid molecules of the presently-disclosed subject matter 
where an arginine is speci?ed by a codon, the codon can be 
altered to any of the corresponding codons described above 
without altering the encoded polypeptide. It is understood 
that U in an RNA sequence corresponds to T in a DNA 
sequence. 
“Conservative variants” are proteins or enzymes in which a 
given amino acid residue has been changed without altering 
overall conformation and function of the protein or enzyme, 
including, but not limited to, replacement of an amino acid 
with one having similar properties, including polar or non 
polar character, size, shape and charge. Amino acids other 
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than those indicated as conserved may differ in a protein or 
enzyme so that the percent protein or amino acid sequence 
similarity between any two proteins of similar function may 
vary and can be, for example, at least 30%, at least 50%, at 
least 70%, at least 80%, at least 90%, at least 95%, at least 
98% or at least 99%, as determined according to an alignment 
scheme. 
Non-conservative modi?cations of a particular polypep 
tide are those which substitute any amino acid not character 
ized as a conservative substitution. For example, any substi 
tution which crosses the bounds of the six groups set forth 
above. These include substitutions of basic or acidic amino 
acids for neutral amino acids, (e.g., Asp, Glu, Asn, or Gln for 
Val, lle, Leu or Met), aromatic amino acid for basic or acidic 
amino acids (e.g., Phe, Tyr or Trp forAsp, Asn, Glu or Gln) or 
any other substitution not replacing an amino acid with a like 
amino acid. Basic amino acids include lysine (K), arginine 
(R), histidine (H); acidic amino acids include aspartic acid 
(D), glutamic acid (E); uncharged polar amino acids include 
glycine (G), asparagine (N), glutamine (Q), serine (S), threo 
nine (T), tyrosine (Y), cysteine (C); nonpolar amino acids 
include alanine (A), valine (V), leucine (L), isoleucine (I), 
proline (P), phenylalanine (F), methionine (M), tryptophan 
(W); beta-branched amino acids include threonine (T), valine 
(V), isoleucine (I); aromatic amino acids include tyrosine 
(Y), phenylalanine (F), tryptophan (W), histidine (H). 
A polynucleotide, polypeptide, or other component is “iso 
lated” when it is partially or completely separated from com 
ponents with which it is normally associated (other proteins, 
nucleic acid molecules, cells, synthetic reagents, etc.). A 
nucleic acid molecule or polypeptide is “recombinant” when 
it is arti?cial or engineered, or derived from an arti?cial or 
engineered protein or nucleic acid molecule. For example, a 
polynucleotide that is inserted into a vector or any other 
heterologous location, e.g., in a genome of a recombinant 
organism, such that it is not associated with nucleotide 
sequences that normally ?ank the polynucleotide as it is 
found in nature is a recombinant polynucleotide. A protein 
expressed in vitro or in vivo from a recombinant polynucle 
otide is an example of a recombinant polypeptide. Likewise, 
a polynucleotide sequence that does not appear in nature, for 
example a variant of a naturally occurring gene, is recombi 
nant. For example, an “isolated” nucleic acid molecule is one 
which is separated from other nucleic acid molecules which 
are present in the natural source of the nucleic acid molecule. 
For example, with regards to genomic DNA, the term “iso 
lated” includes nucleic acid molecules which are separated 
from the chromosome with which the genomic DNA is natu 
rally associated. Typically, an “isolated” nucleic acid mol 
ecule is free of sequences which naturally ?ank the nucleic 
acid molecule (i.e., sequences located at the 5' and 3' ends of 
the nucleic acid molecule) in the genomic DNA of the organ 
ism from which the nucleic acid molecule is derived. For 
example, in various embodiments, the isolated nucleic acid 
molecule can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 
kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally 
?ank the nucleic acid molecule in genomic DNA of the cell 
from which the nucleic acid molecule is derived. Moreover, 
an “isolated” nucleic acid molecule, such as a cDNA mol 
ecule, can be substantially free of other cellular material, or 
culture medium when produced by recombinant techniques, 
or substantially free of chemical precursors or other chemi 
cals when chemically synthesized. 
In some embodiments, a polypeptide provided herein 
includes amino acid residue substitutions that correspond to 
positions in a particular sequence at least 80%, 85%, 90%, 
95%, 98% or 99% of the time. In other words, the presently 




























